Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase II drugs for Diabetic Macular Edema have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lenvatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lenvatinib overview

AIV-007 (lenvatinib) is under development for the treatment of neovascular age-related macular degeneration, diabetic macular edema, benign prostatic hyperplasia and solid tumor. It is administered by periocularly (ophthalmic), intravitreal and intraprostatic route. It targets vascular endothelial growth factor 1,2 (VEGFR), platelet-derived growth factor receptor (alpha, beta) (PDGFR), fibroblast growth factor receptor (1,2,3,4) (FGFR) and transforming growth factor-beta 1, KIT, RET. The drug candidate is developed based on JEL technology.

AiViva BioPharma overview

AiViva BioPharma (AiViva) is a clinical-stage biotech company that develops drug products with the potential to profoundly reduce the treatment burden for patients and physicians and which may transform current treatment paradigms. AiViva is headquartered in Newport Beach, California, the US.

For a complete picture of Lenvatinib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.